Completed PHASE1 INTERVENTIONAL 1-arm NCT00954278

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Bayer

Conditions Carcinoma, Non Small Cell Lung

Interventions sorafenib

Updated 8 times since 2017 Last updated: Nov 13, 2019 Started: Jul 28, 2009 Primary completion: Dec 23, 2015 Completion: Dec 23, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00954278, this PHASE1 trial focuses on Carcinoma, Non Small Cell Lung and remains completed. Sponsored by Bayer, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1
Apr 2019 — Dec 2019 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States